CBio A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  10.5% 9.3% 19.5% 5.0% 3.5%  
Credit score (0-100)  23 25 6 42 53  
Credit rating  BB BB B BBB BBB  
Credit limit (kDKK)  0.0 0.0 -0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  -1,814 -1,913 -1,104 5,483 4,663  
EBITDA  -4,891 -9,522 -9,317 -1,441 -452  
EBIT  -5,141 -11,159 -11,185 -1,441 -452  
Pre-tax profit (PTP)  -5,187.6 -11,558.1 -11,777.5 -2,177.8 -904.5  
Net earnings  -3,901.4 -8,556.2 -8,975.7 -621.6 -79.6  
Pre-tax profit without non-rec. items  -5,188 -11,558 -11,778 -2,178 -904  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  5,058 6,922 7,015 4,847 2,679  
Shareholders equity total  6,822 8,265 -710 5,743 12,279  
Interest-bearing liabilities  5,969 6,642 7,327 7,740 6,433  
Balance sheet total (assets)  15,877 18,775 14,750 22,749 35,747  

Net Debt  -336 1,897 6,627 5,671 -363  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -1,814 -1,913 -1,104 5,483 4,663  
Gross profit growth  -424.1% -5.5% 42.3% 0.0% -15.0%  
Employees  4 11 11 9 6  
Employee growth %  0.0% 175.0% 0.0% -18.2% -33.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  15,877 18,775 14,750 22,749 35,747  
Balance sheet change%  1,991.0% 18.3% -21.4% 54.2% 57.1%  
Added value  -4,890.7 -9,522.5 -9,317.1 427.0 -452.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  4,807 228 -1,775 8,950 6,629  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 -3.0 -4.0 -5.0 -5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  283.5% 583.3% 1,013.0% -26.3% -9.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -61.6% -64.4% -65.3% -7.5% -1.4%  
ROI %  -75.8% -76.6% -86.2% -11.6% -2.3%  
ROE %  -103.4% -113.4% -78.0% -6.1% -0.9%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  80.4% 77.6% 40.8% 56.7% 50.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  6.9% -19.9% -71.1% -393.6% 80.3%  
Gearing %  87.5% 80.4% -1,031.6% 134.8% 52.4%  
Net interest  0 0 0 0 0  
Financing costs %  2.3% 6.4% 8.5% 9.8% 7.1%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  3.3 4.0 1.1 0.7 0.7  
Current Ratio  3.3 4.0 1.1 0.7 0.7  
Cash and cash equivalent  6,305.6 4,745.1 700.6 2,068.3 6,796.0  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  7,251.1 8,217.4 546.5 -2,154.5 -4,195.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -1,223 -866 -847 47 -75  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -1,223 -866 -847 -160 -75  
EBIT / employee  -1,285 -1,014 -1,017 -160 -75  
Net earnings / employee  -975 -778 -816 -69 -13